Cable Hill Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Cable Hill Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-62	Closed	-$7K	–	940
2018 Q1	$7K	Sell	62 -122	-66%	-$14.6K	﹤0.01%	594
2017 Q4	$23K	Sell	184 -276	-60%	-$33.6K	0.01%	367
2017 Q3	$65K	Buy	460 +62	+16%	+$8.42K	0.03%	209
2017 Q2	$48K	Buy	398 +263	+195%	+$30.6K	0.03%	155
2017 Q1	$16K	Hold	135	–	–	0.01%	309
2016 Q4	$17K	Sell	135 -5	-4%	-$612	0.01%	301
2016 Q3	$17K	Buy	140 +5	+4%	+$644	0.01%	318
2016 Q2	$17K	Hold	135	–	–	0.01%	281
2016 Q1	$20K	Hold	135	–	–	0.02%	241
2015 Q4	$26K	Hold	135	–	–	0.02%	205
2015 Q3	$22K	Hold	135	–	–	0.02%	238
2015 Q2	$25K	Hold	135	–	–	0.02%	251
2015 Q1	$23K	Hold	135	–	–	0.02%	259
2014 Q4	$25K	Buy	+135	New	+$25K	0.02%	249

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cable Hill Partners's ALXN Position: Q2 2018 in Review

Cable Hill Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 62 shares — an estimated $7K sold.

Cable Hill Partners first reported a position in ALXN in Q4 2014 and held it in 14 quarters. The position peaked at $65K in Q3 2017. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Cable Hill Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Cable Hill Partners sold 62 Alexion Pharmaceuticals shares in Q2 2018, an estimated $7K.
Cable Hill Partners first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 14 quarters.
Cable Hill Partners's Alexion Pharmaceuticals position peaked at $65K in Q3 2017.
601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Cable Hill Partners's 13F filing for Q2 2018, filed 3 Aug 2018.